Abstract
Gynecologic cancers are associated with a high risk of venous thromboembolism (VTE). Recent ASCO clinical practice guidelines have recommended all patients undergoing pelvic surgery for cancer, including minimally invasive surgery (MIS), receive 7–10 days of pharmacologic thromboprophylaxis, extended up to 4 weeks for high-risk patients. High risk is not well defined in the guidelines. The Caprini and Khorana score are VTE risk assessment tools that have been clinically validated in other populations but not in patients with uterine cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
